Re-classify the myositis subtype before escalating treatment
The historical label 'polymyositis' can conceal several biologically different diseases. Charité's dedicated Myositis Center explicitly distinguishes dermatomyositis, immune-mediated necrotizing myopathy, antisynthetase syndrome and inclusion-body myositis. A German second opinion is most useful when it tests whether the existing subtype label still fits the clinical, serological, imaging and pathology pattern.
- Pattern and speed of proximal or distal muscle weakness
- Skin findings suggesting dermatomyositis
- Dysphagia or respiratory symptoms
- CK and other muscle-enzyme trends
- Myositis-specific and myositis-associated antibodies
- Prior muscle MRI, EMG and biopsy findings
Use clinical examination, laboratory testing, EMG and muscle imaging together
Charité's Myositis Center lists neurological examination, electrophysiology, CK, myositis-specific autoantibodies, inflammatory markers, genetics and muscle biopsy within its specialist diagnostic pathway. Heidelberg and Freiburg neuromuscular clinics also use EMG/ENG and modern muscle imaging, with biopsy available when needed. No single abnormal CK value or antibody result should replace the full clinical pattern.
Muscle biopsy is selected rather than automatic
Biopsy can be important when the subtype remains uncertain, when IBM or another structural myopathy is suspected, or when serology and imaging do not explain the weakness. Specialist review can help choose an appropriate muscle and avoid repeating a non-diagnostic biopsy without a clear question.
Dermatomyositis requires more than muscle-strength monitoring
Dermatomyositis can involve skin and other organs. Charité notes that certain autoantibody patterns can add clinically relevant information, including associations that may influence malignancy screening in adults. Screening should therefore be individualized by age, subtype, antibody profile and symptoms rather than treated as one fixed test package.
Antisynthetase syndrome may require lung-focused assessment
Antisynthetase syndrome can combine inflammatory muscle disease with systemic manifestations, particularly interstitial lung disease. New or progressive breathlessness should prompt timely local medical assessment; a planned German review can then coordinate neurology/rheumatology with pulmonary evaluation when the patient is stable.
Immunotherapy should follow the confirmed immune-mediated subtype
German neuromuscular and neuroimmunology services use individualized immunomodulatory or immunosuppressive treatment for inflammatory muscle diseases. Freiburg's neurological day clinic documents IV immunoglobulin and selected immunosuppressive/biologic treatment pathways for systemic neuropathies and myopathies, while Heidelberg's neuroimmunology clinic offers complex outpatient immunotherapy. The specific drug and sequence should depend on subtype, severity, organ involvement, prior response and safety profile rather than on the word 'myositis' alone.
Inclusion-body myositis is a different therapeutic problem
Charité describes IBM as a chronic progressive disease with both inflammatory and degenerative muscle changes and notes the lack of a satisfactory specific therapy. This is why an IBM pathway should not simply repeat the immunosuppression strategy used for other inflammatory myopathies. Function, falls, hand weakness, swallowing and assistive-device planning become central parts of care.
Rehabilitation and swallowing care belong in the core plan
Myositis can leave substantial weakness even after inflammation improves. Freiburg and Heidelberg neuromuscular services integrate rehabilitation and interdisciplinary care. The plan may include physiotherapy, occupational therapy, energy conservation, fall prevention, speech/swallow assessment and nutrition support according to the phenotype.
Know when the problem is too urgent for planned medical travel
Rapidly worsening weakness, inability to stand or walk, new respiratory difficulty, aspiration, severe dysphagia, chest symptoms or rapidly progressive systemic illness requires urgent local assessment. Stabilization should come before international travel arrangements.
What to send for a German myositis second opinion
A useful file lets the center judge both the subtype and the objective response to previous therapy.
- Neurology, rheumatology and dermatology reports
- CK and other muscle-enzyme trends
- Myositis antibody panel with laboratory method if available
- EMG/ENG reports
- Muscle MRI images and report
- Muscle-biopsy pathology report and, if possible, slides/digital pathology access
- Lung testing or chest CT when interstitial lung disease is suspected or known
- Swallowing assessments
- Complete immunotherapy history with dose, dates, response and adverse effects
- A specific question: subtype confirmation, biopsy review, refractory disease, organ screening or long-term treatment plan
Official sources
Sources last checked 2026-09-01. Clinical pathways, eligibility and hospital procedures can change; confirm current requirements directly with the treating center.
- Myositis Center – patient information — Charité – Universitätsmedizin Berlin ↗
- Myositis Center – diagnostics and treatment services — Charité – Universitätsmedizin Berlin ↗
- Neuromuscular outpatient clinic — Heidelberg University Hospital ↗
- Neuroimmunology outpatient clinic — Heidelberg University Hospital ↗
- Neuromuscular outpatient clinic — University Medical Center Freiburg ↗
- Neurological day clinic – systemic neuropathies and myopathies — University Medical Center Freiburg ↗